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Left ventricular assist devices (LVADs) are fast becoming stan-
dard of care for patients with advanced heart failure. How-
ever, despite continuous improvement in VAD technology, 
there remains a significant early postoperative morbidity and 
mortality in this extreme patient group. The aim of the cur-
rent study was to explore the short-term outcomes and pre-
dictors for 90 day mortality in the patients after implantation 
of  continuous-flow LVAD. Perioperative clinical, echocardio-
graphic, hemodynamic, and laboratory data of 90 day survivors 
and nonsurvivors were collected and compared retrospectively. 
Multivariate logistic regression analysis was performed on uni-
variate predictors for 90 day mortality with an entry criterion 
of p < 0.1. Between July 2006 and May 2012, 117 patients 
underwent implantation of a continuous-flow LVAD as a bridge 
to transplantation: 71 (60.7%) HeartMate II (Thoratec Corp, 
Pleasanton, CA) and 46 (39.3%) HVAD (HeartWare Inter-
national, Framingham, MA). All-cause 90 day mortality was 
17.1%. Multivariate analysis revealed higher preoperative cen-
tral venous pressure (odds ratio [OR], 1.18; 95% confidence 
interval [CI], 1.014–1.378; p = 0.033) and higher age (OR, 1.14; 
95% CI, 1.01–1.38; p = 0.045) as the only independent predic-
tors for 90 day mortality. Optimization of preoperative volume 
status, preload, and right heart function as well as  age-based 
selection of candidates for LVAD support are the critical fac-
tors influencing early outcome after  continuous-flow LVAD 
implantation. ASAIO Journal 2014; 60:162–169.
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Left ventricular assist devices (LVADs) have become efficient 
treatment for a large number of patients with advanced heart 
failure either as a bridge to transplant, bridge to recovery, or 
as destination therapy.1–8 Technological development and 
increasing clinical implementation have significantly improved 
the survival in patients supported with  continuous-flow 
(CF) LVADs and are associated with decreased incidence of 
adverse events and a better quality of life compared to pul-
satile devices.5 However, despite continuous improvement in 
the LVAD technology and results, the patients on mechanical 
support still experience a significant mortality, particularly in 
the early postoperative phase.2,9,10 Also, because the number of 
cardiac transplantations has been significantly restricted due to 
donor organ shortage, the LVADs have been increasingly used 
particularly as a bridge to transplantation. Despite decreased 
mortality and morbidity, the hazard of LVAD-related complica-
tions which is highest in the early phase after listing for trans-
plant can dramatically worsen the survival on the waiting list.11
The aim of this study was to present outcomes and to evalu-
ate the risk factors for early (90 day) mortality after CF-LVAD 
implantation as a bridge to transplantation in patients with 
advanced heart failure in view of optimizing the patient selec-
tion and the operative strategy in this extreme patient group.
Methods
All 117 consecutive patients who received a CF-LVAD for 
end-stage heart failure at our institution from July 2006 up to 
May 2012 were included in this retrospective observation. All 
the patients were eligible for heart transplantation and LVADs 
were implanted as a bridge to transplantation. The patients on 
preoperative temporary mechanical circulatory support includ-
ing intraaortic balloon pump (IABP), extracorporeal membrane 
oxygenation (ECMO), as well as short- and long-term VADs 
were also included in the study. The primary end point was 
overall survival to 90 days after LVAD implantation (survival 
on LVAD support, after heart transplant or after explantation 
for myocardial recovery). The secondary end points were 
perioperative clinical characteristics and adverse events that 
could have an impact on early postoperative mortality. All the 
patients completed a follow-up period of at least 90 days and 
were divided into two groups depending on the 90 day sur-
vival. The demographic and perioperative variables of the 90 
day survivors and nonsurvivors were compared to identify the 
predictors of 90 day overall mortality.
The analysis was performed using a prospectively maintained 
institutional patient database. The variables evaluated included 
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the following: baseline characteristics (patient’s demographics: 
sex, age, height, weight, body mass index, human leukocyte 
antigen, and cytomegalovirus infection status, cause of heart 
failure, as well as additional disorders); preoperative laboratory 
parameters (white blood cell count, C-reactive protein, total bil-
irubin, alanine aminotransferase, blood urea nitrogen [BUN], 
and creatinine); baseline hemodynamic characteristics (heart 
rate, heart rhythm, mean arterial pressure, mean pulmonary 
artery pressure, central venous pressure [CVP], pulmonary cap-
illary wedge pressure [PCWP], cardiac output, central venous 
saturation, and echocardiographic data [ejection fraction, left 
ventricular diastolic (LVDD) and systolic (LVSD) diameters]) as 
well as further preoperative clinical data (preoperative length 
of stay [LOS], use of an IABP, ECMO, or short- or long-term 
VAD, ventilator or inotropic support, presence of an implant-
able cardioverter defibrillator [ICD], body temperature, blood 
culture status, presence of major infection, and condition after 
sternotomy or noncardiac surgery); intraoperative data  (on-/
off-pump approach, use of aortic cross-clamp, theater time, 
conventional/double-tunnel driveline placement technique); 
and postoperative variables (inotropic or ventilator support > 7 
days, right ventricular failure [RVF] requiring short- or long-term 
mechanical support, acute renal failure [ARF] requiring renal 
replacement therapy, respiratory insufficiency, tracheostomy, 
ECMO, early postoperative infections, bleeding and transfusion 
requirements, postoperative intensive care unit, and total LOS).
Statistical Analysis
All data were presented as continuous or categorical vari-
ables. The continuous data were evaluated for normality using 
one-sample Kolmogorov–Smirnov test. Univariate analysis was 
performed using either Student’s t-test or Mann–Whitney U test 
for normal and nonnormal continuous variables, respectively. 
Pearson’s χ2 or Fisher exact tests were used for categorical data 
dependent on the minimum expected count in each cross tab.
Kaplan–Meier actuarial survival estimate was generated to 
analyze post-LVAD survival of the entire cohort. All data were 
analyzed using Statistical Package for Social Sciences, version 
20.0 (SPSS Inc., Chicago, IL) and are expressed as the mean 
± standard deviation in case of normal distributed or median 
(interquartile range) in case of nonnormal distributed continu-
ous variables. The categorical data are expressed as total num-
bers and percentages. Multivariate logistic regression analysis 
was performed on univariate predictors for 90 day mortality 
with an entry criterion of p < 0.1.
Results
Perioperative Outcome
A total of 117 patients with severe end-stage heart failure (mean 
age of 44 ± 13 years; male/female ratio, 97/20) underwent implan-
tation with the HeartMate II (Thoratec Corp, Pleasanton, CA) 
(n = 71, 60.7%) or HVAD (HeartWare International, Framingham, 
MA) (n = 46, 39.3%) CF-LVAD at our institution between July 
2006 and May 2012. The cause of the heart failure was dilated 
cardiomyopathy (n = 99, 84.6%), ischemic cardiomyopathy 
(n = 14, 12%), postpartum dilated cardiomyopathy (n = 2, 1.7%), 
and hypertrophic obstructive cardiomyopathy (n = 2, 1.7%).
The mean preoperative LOS in hospital was 23.5 ± 19.1 
days. Nine patients (7.7%) required preoperative mechanical 
ventilation, 88 (75.2%) inotropic support, 24 (20.5%) IABP, 7 
(6.0%) ECMO, 13 (11.1%) short-term VAD, and 11 (9.4%) long-
term VAD in the form of isolated LVAD (n = 9, 7.7%) or biven-
tricular assist device support (n = 12, 10.3%). Eleven patients 
(11.3%) had preoperative cardiac arrhythmias with hemody-
namic compromise, 31 (26.5%) had a previous sternotomy, 
and 54 (46.2%) had an ICD. A preoperative major infection 
was present in seven (6.0%) patients out of whom four (3.4%) 
were presented with positive blood cultures. Preoperative mean 
body temperature accounted for 37.1°C ± 0.7°C. There were 
no patients with previous cardiac transplantation in this cohort.
Majority of the LVAD implantations were performed through 
a median sternotomy (n = 113, 96.6%) on cardiopulmonary 
bypass without cross-clamping the aorta (n = 96, 82.1%). Four 
patients, who received HVAD, underwent minimally invasive 
LVAD implantation through bilateral anterior minithoracotomy. 
In 25 patients (21.4%), a modified C-shaped double tunnel tech-
nique was used for the placement of subcutaneous driveline.
The overall 90 day mortality was 17.1% (Figure 1) and mean 
LVAD support duration was 434.3 ± 410.5 days. Of the patients 
who died within 90 days (n = 20, 17.1%) of LVAD implantation, 
18 (90%) died on primary LVAD support and 2 (10%) underwent 
the device exchange in the meantime. In the 90 day survival 
group (n = 97, 82.9%), 18 patients (18.6%) died on support after 
90 days, 9 (9.3%) underwent LVAD exchange and were alive at 
the study cut off, 39 (40.2%) were on ongoing VAD support, 19 
(19.6%) underwent device explantation for myocardial recovery, 
and 12 (12.4%) were transplanted during the follow-up period. 
The perioperative bleeding requiring reexploration and opera-
tive hemostasis occurred in 32 (27.8%) patients whereas the 
mean transfusion rate was 8.7 ± 9.9, 5.4 ± 7.3, and 2.1 ± 3.2 units 
for red blood cells (RBCs), fresh frozen plasma, and platelets, 
respectively. Thirty-five (32.4%) patients required prolonged (>7 
days) postoperative inotropic support and 19 (17.8%) required 
prolonged mechanical ventilation. Two (1.7%) patients required 
postoperative venoarterial ECMO support due to device failure. 
Twenty-nine (24.8%) patients suffered post-LVAD RVF requiring 
temporary mechanical right ventricular support with CentriMag 
(Levitronix, Zurich, Switzerland) short-term VAD and two of 
them were subsequently upgraded to a long-term right ventricu-
lar assist device (RVAD) with Jarvik 2000 (Jarvik Heart Inc, New 
York, NY). Additional postoperative complications included ARF 
requiring renal replacement therapy (n = 33, 28.7%), respira-
tory insufficiency requiring reintubation for mechanical ventila-
tion (n = 24, 21.1%), or surgical tracheostomy (n = 13, 11.6%) 
and infections (n = 63, 53.8%). Percutaneous side infections 
(PSIs) with the need for at least intravenous antibiotic therapy 
occurred in 33 (28.2%) cases whereas 10 among them (8.5%) 
required additional surgical treatment, such as wound debride-
ment, drainage, or  vacuum-assisted closure therapy. The median 
infection-free survival was 219.0.0 ± 182.8 days, and the most 
frequent organisms isolated in the patients with postoperative 
PSI were Staphylococcus aureus and Enterobacter and Coliform 
species.
Univariate Analysis
A subgroup analysis of the 90 day survivors and nonsur-
vivors is presented in Tables 1–6. The survivors were signifi-
cantly younger (43.0 ± 13.3 vs. 49.9 ± 9.2, p = 0.008) with 
the trend toward less frequent peripheral vascular disease 
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(1.0% vs. 10.0%, p = 0.075) (Table 1). The preoperative 
laboratory parameters (Table 2) and intraoperative variables 
(Table 5) were comparable between both groups. The evalu-
ation of preoperative hemodynamic and echocardiographic 
parameters revealed a significantly higher CVP (19.5 ± 8.6 
vs. 13.6 ± 7.6, p = 0.011) as well as significantly lower LVDD 
and LVSD in the 90 day nonsurvivor group compared to 
the 90 day survivor group (Table 3). Moreover, there was a 
trend toward higher rate of preoperative long-term mechani-
cal support resulting in the LVAD exchange compared to 
primary LVAD implantation in the 90 day nonsurvival group 
(20% vs. 7.2%, p = 0.093). This group was also associated 
with the higher perioperative transfusion rate with RBCs (13 
[4, 19] vs. 5 [2, 11], p = 0.014) and platelets (3 [1, 6] vs. 1 
[0, 2], p = 0.003). Finally, the nonsurvivors were more pre-
disposed to prolonged (>7 days) postoperative mechanical 
ventilation (42.9% vs. 14%, p = 0.017) and inotropic support 
(53.3% vs. 29.0%, p = 0.078) and had a significantly higher 
rate of postoperative ARF requiring hemofiltration (66.7% vs. 
21.6%, p < 0.001).
Figure 1. Kaplan–Meier survival curve for patients undergoing continuous-flow left ventricular assist device implantation. The patients were 
censored when they underwent cardiac transplantation, device exchange, or device explantation for myocardial recovery.
Table 1.  Patient’s Baseline Preoperative Demographics
90 Day Survivors 90 Day Nonsurvivors p
Age (years) 43.0 ± 13.3 49.9 ± 9.2 0.008
Female 14 (14.4%) 6 (30.0%) 0.108
BMI 25.7 ± 4.1 25.5 ± 5.9 0.927
Mean INTERMACS class 2.5 ± 1.1 2.13 ± 0.83 0.199
INTERMACS class 1 12 (12.1%) 4 (23.5%) 0.250
Primary diagnosis
  DCM 83 (85.6%) 16 (80.0%) 0.508
  ICM 11 (11.3%) 3 (15.0%) 0.705
  PPDCM 2 (2.1%) 0 1.000
  HOCM 1 (1.0%) 1 (5.0%) 0.314
  CHD 0 0
Comorbidities
  COPD 2 (2.1%) 0 1.000
  Diabetes mellitus 12 (12.4%) 5 (25.0%) 0.166
  PVD 1 (1.0%) 2 (10.0%) 0.075
Boldface indicates p < 0.100.
BMI, body mass index; CHD, congenital heart defect; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; 
HOCM, hypertrophic obstructive cardiomyopathy; ICM, ischemic cardiomyopathy; PPDCM, postpartum dilated cardiomyopathy; PVD, pe-
ripheral vascular disease.
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Independent Predictors of 90 Day Mortality
The predictors of the 90 day mortality obtained by multi-
variate regression analysis were a higher preoperative CVP 
(odds ratio, 1.18; 95% confidence interval [CI], 1.014–1.378; 
p = 0.033) and a higher age (odds ratio, 1.14; 95% CI, 1.01–
1.38; p = 0.045). To provide a cutoff point for age and CVP, 
both continuous variables were converted into categorical 
variables and multiple serial χ2 testing was performed with 
stepwise threshold progression to determine maximal diver-
gence between survivors and nonsurvivors. This approach 
established cutoff points for age and CVP and identified age > 
45 years (p = 0.024) and CVP > 18 mm Hg (p = 0.042) as the 
most significant predictors of the 90 day mortality after LVAD 
implantation (Figure 2). Other univariate predictors did not 
reach the statistical significance in the multivariate analysis.
Discussion
The current report represents a single-center experience 
with the two CF-LVADs (HeartMate II and HVAD) that have 
increasingly been used in our institution in the recent years. 
The two devices have some similarities and divergences. The 
HeartMate II is an axially configured pump with the rotor being 
parallel to the direction of flow. The HVAD uses a centrifugal 
blood pump that provides flow using hydrodynamic and cen-
trifugal forces. The devices contain only one electromagneti-
cally suspended moving part resulting in great durability and 
can generate a flow of up to 10 L/min. Because of its smaller 
size and weight, the HVAD is usually implanted intrapericardi-
ally without a need for additional pump pocket formation or 
can be implanted using minimal invasive access.9,12 By con-
trast, the HeartMate II is usually placed in a preperitoneal loca-
tion requiring LVAD pocket.13 Nevertheless, the type of device 
used did not appear to be a predictor for early mortality in 
our analysis: 15.7% of patients on HeartMate II and 19.1% of 
patients on HeartWare died within the first 90 days postopera-
tively (p = 0.629).
We presented perioperative morbidity and mortality after 
 CF-LVAD implantation which in general are comparable to 
those of other series.4,6,9 However, unlike the other series, the 
patients who had been on ECMO, short- and even  long-term 
mechanical circulatory support preoperatively were not 
excluded from this study for the purpose of evaluating the 
influence of previous mechanical support and the impact of 
the second surgery as possible risk factors on early mortal-
ity. Significantly, higher risk of bleeding and higher morbidity 
and mortality associated with the VAD exchange have been 
described previously.5 This outcome was partially reflected in 
our results with higher percentage of patients who had been 
on long-term VAD support preoperatively (Table 4) with signifi-
cantly higher transfusion requirements with RBCs and platelets 
(Table 6) in 90 day nonsurvivor group. Even though, the dif-
ference in preoperative support with the long-term VAD did 
not reach statistical significance (p = 0.093), the trend toward 
higher mortality in this subgroup has an obvious clinical rel-
evance. The postoperative complications which usually occur 
after 90 days of LVAD implantation were logically excluded 
from this observation.
Risk factors for long-term mortality in patients undergoing 
LVAD implantation have been reported in previous research. 
Table 2.  Preoperative Laboratory Parameters
90 Day Survivors 90 Day Nonsurvivors p
BUN (mg/dl) 9.0 ± 4.5 10.7 ± 5.2 0.141
Creatinine (mg/dl) 103 (84, 127) 104 (82, 180) 0.467
Total bilirubin (mg/dl) 33.0 ± 22.7 35.8 ± 19.1 0.614
ALT (unit/L) 33 (19, 62) 31 (22, 66) 0.875
WCC (×109/L) 8 (7, 11) 10 (7, 12) 0.106
CRP (mg/L) 18 (7, 47) 44 (10, 68) 0.102
ALT, alanine aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; WCC, white blood cell count.
Table 3.  Preoperative Hemodynamic and Echocardiographic Data
90 Day Survivors 90 Day Nonsurvivors p
Heart rate (bpm) 88.1 ± 20.4 86.8 ± 19.0 0.802
MAP (mm Hg) 76.5 ± 10.2 72.4 ± 10.2 0.142
CVP (mm Hg) 13.6 ± 7.6 19.5 ± 8.6 0.011
MPAP (mm Hg) 39.7 ± 11.5 35.1 ± 14.5 0.248
PCWP (mm Hg) 26.9 ± 7.2 29.3 ± 4.7 0.399
CO (L) 3.3 ± 1.0 3.7 ± 1.0 0.346
SvO2 (%) 55.7 ± 17.3 56.3 ± 18.6 0.928
LVDD (mm) 70.1 ± 11.0 63.6 ± 11.0 0.024
LVSD (mm) 62.4 ± 10.7 54.9 ± 13.0 0.013
EF (%) 0.308
  <20 39 (51.3%) 6 (37.5%)
  20–35 25 (32.9%) 5 (31.2%)
  36–55 10 (13.2%) 5 (31.2%)
  >55 2 (2.6%) 0
Boldface indicates p < 0.100.
CO, cardiac output; CVP, central venous pressure; EF, ejection fraction; LVDD, left ventricular diastolic diameter; LVSD, left ventricular 
systolic diameter; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; SvO2, 
central venous saturation.
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It was shown that age and RVF requiring RVAD were significant 
risk factors for long-term mortality in such patients.14 However, 
due to limited device selection, a pulsatile extracorporeal 
LVAD which was primarily designed for short-term support was 
used in the majority of cases. Furthermore, it is interesting to 
note that in contrast to that and to our study, Adamson et al.15 
did not find significant differences in outcome after CF-LVAD 
implantation in patients ≥70 years of age and <70 years of age 
indicating that age should not be an absolute contraindication 
for LVAD implantation in elderly patients. The outcome of the 
entire population in that study was similar to our results.
In an another study about the risk factors for early mortality 
in INTERMACS level 1 patients after LVAD implantation, higher 
preoperative creatinine was found to be the only independent 
predictor of 90 day mortality in a critical subpopulation of 
41 patients.10 The degree of preoperative renal dysfunction 
with high creatinine levels (1.63 ± 0.98 mg/dl) and BUN lev-
els (36.9 ± 21.8 mg/dl) in that patient group could have led 
to increased perioperative requirement for hemodialysis and 
further complications resulting from this condition influencing 
early mortality. Furthermore, most patients in this subpopu-
lation underwent implantation of a pulsatile extracorporeal 
LVAD questioning comparability of the results. The incidence 
of postoperative ARF after CF-LVAD implantation reported pre-
viously ranges between 8.7% and 13%4,6,16 and seems to be 
considerably lower than experienced in our study. The reason 
for this discrepancy might be the fact that the patients who 
were at high risk for postoperative complications, such as the 
patients on ECMO or other mechanical circulatory support, 
were not excluded in our study. The rate of postoperative ARF 
requiring renal replacement therapy in our population in the 
univariate analysis was significantly higher in the 90 day non-
survival group (p < 0.001). This finding corroborates the results 
of Borgi et al.17 which suggested an association between the 
postoperative ARF and a higher mortality at 30, 180, and 360 
days after LVAD implantation. Moreover, similar to our results, 
Sandner et al.18 demonstrated that the patients with post-LVAD 
ARF had significantly lower survival regardless of pre-LVAD 
renal function. Nevertheless, this variable did not reach statisti-
cal significance in the logistic regression analysis (odds ratio, 
1.71; 95% CI, 1.15–19.12; p = 0.061) and was not found to be 
an independent predictor of early mortality in our study.
Another variable which was significantly higher in the 90 
day nonsurvival group in our study was the dependency on 
mechanical ventilation for > 7 days (p = 0.017). Interestingly, 
other clinical signs of respiratory failure, such as a need for 
reintubation or a surgical tracheostomy, were similarly dis-
tributed between the two groups. This controversy can be 
explained by high mortality in 90 day nonsurvivors within the 
first 2 weeks of LVAD implantation which also corroborates 
the previous research.2,9,10 Due to this a number of patients 
with respiratory failure who were ventilated >7 days deceased 
before they would receive a surgical tracheostomy leading to 
a lower number of surgical tracheostomies in the patients with 
respiratory failure.
The need for the reintubation usually occurs during first few 
postoperative days due to atelectasis, pleural effusions, and 
general postoperative weakness. After quick improvement, the 
majority of them can be weaned off ventilator within the first 
postoperative week. This explains why the reintubation and 
Table 4.  Preoperative Clinical Status
90 Day Survivors 90 Day Nonsurvivors p
LOS (days) 24.0 ± 19.1 20.7 ± 19.4 0.481
Temperature (°C) 37.1 ± 0.7 37.0 ± 0.5 0.761
Arrhythmia 9 (11%) 2 (13.3%) 0.677
Positive blood culture 4 (4.1%) 0 1.000
Major infection 5 (5.2%) 2 (10%) 0.342
Previous sternotomy 23 (23.7%) 8 (40.0%) 0.133
Noncardiac surgery 1 (1.0%) 0 1.000
ICD 44 (45.4%) 10 (50%) 0.705
Mechanical ventilation 7 (7.2%) 2 (10.0%) 0.650
Ascites 7 (7.2%) 3 (15%) 0.372
Inotropic support 72 (74.2%) 16 (80%) 0.778
IABP 19 (19.6%) 5 (25.0%) 0.556
ECMO 6 (6.2%) 1 (5.0%) 1.000
STMS 9 (9.3%) 4 (20%) 0.233
LTMS 7 (7.2%) 4 (20%) 0.093
Any MS 15 (15.5%) 6 (30%) 0.196
Boldface indicates p < 0.100.
ECMO, extracorporeal membrane oxygenation; IABP, intraaortic balloon pump; ICD, implantable cardioverter defibrillator; LOS, length of 
stay; LTMS, long-term mechanical support; MS, mechanical support; STMS, short-term mechanical support.
Table 5.  Intraoperative Variables
90 Day Survivors 90 Day Nonsurvivors p
Cross-clamping 15 (15.5%) 6 (30.0%) 0.196
On-pump 82 (84.5%) 14 (70%) 0.196
Theater time (minutes) 300 (250, 435) 330 (300, 420) 0.331
Device implanted 0.629
  HeartMate II 59 (84.3%) 11 (15.7%)
  HeartWare 38 (80.9%) 9 (19.1%)
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tracheostomy did not have direct clinical relevance on the 
90 day mortality in our study. By contrast, the postoperative 
requirement for prolonged mechanical ventilation appeared to 
be more optimal for considering respiratory failure as a risk 
factor for 90 day mortality. Nevertheless, although this param-
eter was significantly higher in the 90 day nonsurvivor group in 
the univariate analysis, it did not reach statistical significance 
in the logistic regression analysis and was not shown to be an 
independent predictor of the 90 day mortality.
In accordance with the results from Yoshioka et al.,10 the pre-
operative serum bilirubin level in our study was not found to 
be a risk factor for early mortality in univariate and logistic 
regression analysis. However, this finding disagrees with those 
of several research studies.19,20 The reason for this inconsis-
tency seems to be more aggressive temporary RVAD support 
protecting from congestive hepatic dysfunction in both studies. 
Moreover, early and ungrudging implantation of RVAD may be 
responsible for perioperative biventricular support, which has 
Table 6.  Early Postoperative Characteristics
90 Day Survivors 90 Day Nonsurvivors p
Inotropic support > 7 days 27 (29.0%) 8 (53.3%) 0.078
Ventilation > 7 days 13 (14.0%) 6 (42.9 %) 0.017
RVAD 22 (22.7%) 7 (35%) 0.263
ECMO 1 (1.0%) 1 (5.0%) 0.314
Hemofiltration 21 (21.6%) 12 (66.7%) <0.001
Reintubation 22 (22.9%) 2 (11.1%) 0.355
Tracheostomy 12 (12.8%) 1 (5.6%) 0.689
Transfusions
  RBC (units) 5 (2, 11) 13 (4, 19) 0.014
  Platelets (units) 1 (0, 2) 3 (1, 6) 0.003
  FFP (units) 3 (0, 6) 5 (2, 14) 0.107
Infections
  Sepsis 13 (13.4%) 0 0.121
  Bronchopulmonary 17 (17.5%) 4 (20%) 0.756
  CVP line 6 (6.2%) 0 0.588
  Urine tract 5 (5.2%) 0 0.586
  Other 9 (9.3%) 3 (15%) 0.429
Boldface indicates p < 0.100.
CVP, central venous pressure; ECMO, extracorporeal membrane oxygenation; FFP, fresh frozen plasma; RBC, red blood cells; RVAD, right 
ventricular assist device.
Figure 2. Mean age and central venous pressure (CVP) in 90 day survivors and nonsurvivors.
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been previously associated with poorer outcome21 not to be a 
predictor of early mortality in our study.
The 90 day mortality in patients with INTERMACS class 
1 in our study was 23.5% which is comparable to previous 
research.10 The mean INTERMACS class was lower in the 90 
day nonsurvivor group compared to the 90 day survivor group 
(2.13 ± 0.83 vs. 2.5 ± 0.11), not reaching a statistical signifi-
cance (p = 0.199). This could be due to the inclusion of the 
patients who underwent LVAD exchange and were stable at 
the time of redo LVAD implantation. However, it cannot be 
ignored that these patients incurred higher perioperative mor-
tality risk due to redo procedure, described previously.5 Also in 
our study, preoperative  long-term LVAD support was one of the 
univariate risk factors for 90 day mortality, and one fifth of the 
patients who died within 90 days were on previous long-term 
LVAD support.
The only influenceable independent risk factor predictive of 
the 90 day mortality in our cohort was the preoperative CVP. 
The data from several sources have identified the role of CVP 
as a critical hemodynamic parameter in the LVAD patients. 
Shiga et al.21 found that the CVP/PCWP ratio was predictive 
of the need for perioperative biventricular support which was 
associated with a significantly poorer survival. The preopera-
tive CVP has also been shown to be significantly higher in 
patients who developed ARF after LVAD implantation which 
also had a negative effect on postoperative outcome.17 Dang 
et al.22 found elevated intraoperative CVP as only independent 
predictor of post-LVAD RVF among all pre- and intraoperative 
hemodynamic parameters. This is partially consistent with our 
results. Being an independent predictor for 90 day mortality, 
an elevated preoperative CVP caused by suboptimal right ven-
tricular function, fluid overloading, or significant pulmonary 
hypertension may have led to development of serious periop-
erative complications causing early post-LVAD mortality. Such 
complications were postoperative ARF requiring hemodialysis, 
prolonged mechanical ventilation, and extended perioperative 
bleeding requiring massive transfusion. However, incidence 
of postoperative RVAD use was not significantly different in 
both groups apparently due to relatively early and aggressive 
use. Nevertheless, a clear clinical trend toward higher rate of 
prolonged inotropic support in the nonsurvivor group which 
is usually associated with RVF pleads for an increased like-
lihood of RVF in this group. Additionally, preoperative LVSD 
and LVDD which were significantly smaller in the nonsurvivor 
group in our study were also significantly smaller in patients 
who developed RVF in the study by Drakos et al.23 and may 
emphasize the role of RVF as a pathophysiological mechanism 
influencing early mortality in our study.
The multivariate logistic regression analysis revealed 
patient’s age as an independent factor for 90 day mortality in 
our study. This finding is in agreement with Shiga et al.20 who 
showed age as an independent risk factor for death after pul-
satile extracorporeal LVAD implantation. Additionally, patients 
60 years and older were shown to have significantly poorer 
survival after the heart transplantation at 30 days and 1 year 
when previously bridged by the CF-LVAD compared to those 
bridged by inotropic support or transplanted directly.24 There-
fore, patient’s age seems to play a crucial role in predicting 
early post-LVAD mortality suggesting appropriate selection of 
the patients for LVAD implantation as a bridge to transplanta-
tion. On the contrary, Adamson et al.15 found no difference 
in the outcome of advanced heart failure patients receiving a 
Heart Mate II LVAD grouped as younger and older than 70 
years of age and concluded that the age should not be an inde-
pendent contraindication and LVAD therapy is suitable for des-
tination therapy in elderly patients.
In conclusion, our analysis based on long-term experience 
with implantation of CF-LVADs allows us to suggest that opti-
mization of the preoperative volume status, preload, and the 
right ventricular function using CVP as an important hemody-
namic indicator is of vital importance for improving the early 
postoperative outcome. Furthermore, patient’s age should be 
considered as an important factor by selecting the candidates 
for CF-LVAD support, particularly as bridge to transplantation.
Study Limitations
The main limitations of this study are its retrospective non-
randomized design and analysis of limited number of patients 
from a single institution. Furthermore, the data collection was 
restricted to the variables which were available in electronic 
or written patient notes and flowcharts. Also, the patients who 
underwent LVAD implantation with concomitant surgical pro-
cedures were not included in the present observation.
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